E-Mail TAMPA, Fla. -- Chimeric antigen receptor T-cell therapy, or CAR T, has been a breakthrough in the treatment of blood cancers such as acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Clinical studies have shown overall response rates of more than 80% with an ongoing response of nearly 40% more than two years after therapy. However, the cellular immunotherapy doesn't work for every patient. Moffitt Cancer Center, one of the leading centers for cellular immunotherapy, is researching why some patients have a better CAR T response than others and what can be done to improve the treatment's effectiveness. In a new study published in